Chief Commercial Officer Jeff Evanson departs Outlook Therapeutics effective immediately

Outlook Therapeutics, Inc.

Jeff Evanson stepped down as Chief Commercial Officer on September 5, 2025.
Departure is without 'cause'; eligible for severance benefits per employment agreement.
No replacement named; interim CEO Lawrence Kenyon continues in role.
Company is a biopharmaceutical firm focused on ophthalmic therapies.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.